Clinical Trials in Szolnok, Hungary
1 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 2
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC90 enrolled41 locationsNCT06731907
Recruiting
Phase 2
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Lung Neoplasm
Merck Sharp & Dohme LLC144 enrolled37 locationsNCT06780098
Recruiting
Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Metastatic CancerAdvanced CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc.200 enrolled120 locationsNCT05853575
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 2
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology227 enrolled33 locationsNCT05208944
Recruiting
Phase 2
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Innate Pharma70 enrolled30 locationsNCT05742607